Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.4%

15 terminated/withdrawn out of 144 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

8%

11 trials in Phase 3/4

Results Transparency

4%

2 of 51 completed trials have results

Key Signals

23 recruiting2 with results11 terminated4 withdrawn

Enrollment Performance

Analytics

N/A
34(42.0%)
Phase 2
22(27.2%)
Phase 1
13(16.0%)
Phase 3
11(13.6%)
Early Phase 1
1(1.2%)
81Total
N/A(34)
Phase 2(22)
Phase 1(13)
Phase 3(11)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (144)

Showing 20 of 144 trials
NCT06322927Completed

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

Role: lead

NCT06136611Not ApplicableRecruiting

Preoperative Preradiotherapy TTFields

Role: lead

NCT04071704Completed

Assessing Health-related Quality of Life in Sarcoma Patients

Role: collaborator

NCT06695494Recruiting

Enabling Genomic Testing in Cancer of Unknown Primary

Role: lead

NCT04960059Completed

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts

Role: lead

NCT07183267Not ApplicableNot Yet Recruiting

Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Years Old, Receiving Radiotherapy

Role: lead

NCT07372885Phase 1Not Yet Recruiting

GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

Role: collaborator

NCT04075305Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Role: collaborator

NCT07057284Enrolling By Invitation

DENTOFACIAL-PBT Stage 2 - Feasibility Study

Role: collaborator

NCT07293598Not Yet Recruiting

Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma

Role: lead

NCT04188119Phase 2Withdrawn

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

Role: lead

NCT07268339Phase 3Not Yet Recruiting

A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.

Role: lead

NCT06965101Not ApplicableRecruiting

To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compression (MSCC) on the Magnetic Resonance Linear Accelerator (MRL) in a Single Appointment and Compare it to the Standard of Care Radiotherapy Pathway

Role: lead

NCT04597580Active Not Recruiting

Personalised Disease Monitoring in Metastatic Breast Cancer

Role: lead

NCT05768412Completed

Radial Artery Access

Role: lead

NCT07202260Active Not Recruiting

Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung

Role: lead

NCT05903430Recruiting

A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)

Role: lead

NCT04748094Completed

Quantification of Abdominal Organ Motion Using MRI

Role: lead

NCT04749134Recruiting

MRI Development for Radiotherapy Planning and Delivery in Non-Patient Volunteers

Role: lead

NCT06868355Recruiting

APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials

Role: collaborator